The More the Better?─Vitamin E TPGS as a Release Enhancer for Ritonavir/PVPVA Amorphous Solid Dispersions
Molecular Pharmaceutics · 2025
DOI: 10.1021/acs.molpharmaceut.5c00620 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Ineke Fahrig und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemical and Chemical Engineering, Laboratory of Thermodynamics, TU Dortmund University, Emil-Figge-Street 70, Dortmund D-44227, Ger…. Hauptthemen laut MEDLINE: Ritonavir, Vitamin E, Vinyl Compounds, Pyrrolidines. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AbbVie Deutschland.
Abstract (Originalsprache)
Amorphous solid dispersions (ASDs) are state-of-the-art formulation strategies for improving the solubility and release of poorly water-soluble, small-molecule active pharmaceutical ingredients (APIs). However, high drug loads (DLs) in ASDs can lead to phase-separation phenomena, resulting in eventually incomplete/collapsed API release, classically referred to as loss of release. This study investigates the role of the surfactant d-α-tocopheryl polyethylene glycol succinate (Vitamin E TPGS) in mitigating this phenomenon in ASDs composed of ritonavir and poly(vinylpyrrolidone-co-vinyl acetate) (PVPVA). As part of the investigations, we developed an improved sampling protocol to differentiate between ASD components molecularly dissolved and those released as nano droplets into the aqueous medium. The results showed that the addition of 3 wt % Vitamin E TPGS enhances release ability up to 30 wt % DL, compared to 25 wt % for the surfactant-free ASD. This enhancement is attributed to Vitamin E TPGS's ability to stabilize discrete RIT-rich domains in the ASD during phase separation. However, at 40 wt % DL, even high Vitamin E TPGS concentrations (up to 10 wt %) did not lead to full release of the API. This indicates that the aforementioned stabilization mechanism failed and could be traced back to a change in the phase separation behavior above an upper limit of Vitamin E TPGS concentrations. This study thus provides insights into the complex release mechanisms of high-DL ritonavir ASDs and the critical role of surfactants such as Vitamin E TPGS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemical and Chemical Engineering, Laboratory of Thermodynamics, TU Dortmund University, Emil-Figge-Street 70, Dortmund D-44227, Germany.
- AbbVie Deutschland GmbH & Co. KG, Development Sciences, R&D, Knollstraße, Ludwigshafen am Rhein D-67061, Germany.
ORCID-Profile: Ineke Fahrig, Samuel Kyeremateng, Gabriele Sadowski, Christoph Brandenbusch
Förderung
- AbbVie Deutschland
Zitieren
APA
Fahrig, I., Walter, S., Kyeremateng, S., Degenhardt, M., Sadowski, G., & Brandenbusch, C. (2025). The More the Better?─Vitamin E TPGS as a Release Enhancer for Ritonavir/PVPVA Amorphous Solid Dispersions. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c00620
Vancouver
Fahrig I, Walter S, Kyeremateng S, Degenhardt M, Sadowski G, Brandenbusch C. The More the Better?─Vitamin E TPGS as a Release Enhancer for Ritonavir/PVPVA Amorphous Solid Dispersions. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.5c00620
BibTeX
@article{Fahrig2025,
author = {Fahrig, Ineke and Walter, Stefanie and Kyeremateng, Samuel and Degenhardt, Matthias and Sadowski, Gabriele and Brandenbusch, Christoph},
title = {The More the Better?─Vitamin E TPGS as a Release Enhancer for Ritonavir/PVPVA Amorphous Solid Dispersions},
journal = {Molecular Pharmaceutics},
year = {2025},
doi = {10.1021/acs.molpharmaceut.5c00620}
}
EUVIMED